Under the agreement, Viatris will receive consideration of up to $3.335 billion in cash and stock. BBL will acquire Viatris' global biosimilars business along with its rights for the in-licensed portfolio. BBL will realize full revenues and profits from the acquired business, expanding its earnings before interest, taxes, depreciation, and amortization (EBITDA) base and strengthening overall financials, thus enabling investments for sustained long-term growth.

BBL has a portfolio of 20 biosimilars, and with this integration, it will become a world leading biosimilars player with one of the broadest and deepest pipelines in the industry. This acquisition will accelerate BBL's direct commercialization strategy for its current and future biosimilars portfolio by providing a direct presence in U.S., Europe, Canada, Japan, Australia, and New Zealand.

Capri EGM acquires R&D build-to-suit for National Resilience
Real estate investment manager Capri EGM has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience.

Integrity Bio, LakePharma become Curia
Curia (formerly AMRI) announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

Asymchem acquires Snapdragon Chemistry
Asymchem Laboratories will acquire Snapdragon Chemistry for $57.94 million. The addition will significantly expand Asymchem's footprint in the U.S.,...

Intellia Therapeutics acquires Rewrite Therapeutics
Intellia Therapeutics has acquired Rewrite Therapeutics, a private biotechnology company focused on advancing novel DNA writing technologies. The acquisition...